恒瑞医药SHR—1139注射液临床试验获批

Core Viewpoint - Heng Rui Medicine's subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1139 injection for ulcerative colitis treatment [1] Group 1 - SHR-1139 injection is a self-developed biological product by Heng Rui Medicine, expected to enhance treatment for ulcerative colitis by inhibiting inflammatory responses and maintaining epithelial barrier mechanisms [1]